Qnovia Secures $16 Million in Series B Financing to Enhance Nicotine Inhaler's Development Qnovia, Inc. has successfully raised $16 million in Series B financing aimed at advancing its RespiRx™ Nicotine Inhaler for smoking cessation.

Qnovia Secures $16 Million in Series B Financing to Enhance Nicotine Inhaler's Development #United_States #Richmond #Qnovia #RespiRx #Nicotine_Inhaler